ReviewCurrent opinion in endocrinology, diabetes, and obesity2011
2011 Update: antigen-specific therapy in type 1 diabetes.
Review in Current opinion in endocrinology, diabetes, and obesity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Diurnal Variation of Islet Autoantibody Titers in Established Type 1 Diabetes Suggests Restricted-Time Sampling Improves Aab Measurement and Detection.Research square · 2026Article
- Screening of Diabetes-Associated Autoantigens and Serum Antibody Profiles Using a Phage Display System.International journal of microbiology · 2024Article
- PRE1BRAZIL Protocol: A Randomized Controlled Trial to Evaluate the Effectiveness and Safety of the DPP-4 Inhibitor Alogliptin in Delaying the Progression of Stage 2 Type 1 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Article
- Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes.Frontiers in endocrinology · 2020Review
- Learning From Past Failures of Oral Insulin Trials.Diabetes · 2018Article
- Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes.Current diabetes reports · 2016Review
- Article
- Molecular Interactions Governing Autoantigen Presentation in Type 1 Diabetes.Current diabetes reports · 2015Review
- Type 1 diabetes: A predictable disease.World journal of diabetes · 2015Review
- Is It Time to Screen the General Population for Type 1 Diabetes?US endocrinology · 2015Article
- Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.Rheumatic diseases clinics of North America · 2014Review
- Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice.PloS one · 2014Article
- Targeting the trimolecular complex.Clinical immunology (Orlando, Fla.) · 2013Review
- The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation.Immunologic research · 2013Review
- The duration of T cell stimulation is a critical determinant of cell fate and plasticity.Science signaling · 2013Article
- Status of autoimmune diabetes 20-year after generation of BDC2.5-TCR transgenic non-obese diabetic mouse.World journal of diabetes · 2013Article
- Article
- Targeting the trimolecular complex: the pathway towards type 1 diabetes prevention.Diabetes technology & therapeutics · 2013Article
- [Update on type 1 diabetes].Der Internist · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewTo update on the clinical trials using antigen-specific therapies in autoimmune diabetes. RECENT
findingsType 1 diabetes is now a predictable disease with the measurement of islet autoantibodies, and the incidence is increasing dramatically. Well tolerated and effective interventions are needed to stop the underlying autoimmune destruction of insulin-producing beta cells. Beta-cell antigens, insulin and glutamic acid decarboxylase, are being used to preserve endogenous insulin production in individuals with new-onset diabetes and to prevent diabetes. The results of antigen-specific immune intervention trials are reviewed and consideration is given to future directions for inducing tolerance in type 1 diabetes. SUMMARY: Antigen-specific immune therapies act by enhancing regulatory T cell function, in animal models often locally and selectively in islets or pancreatic lymph nodes while inhibiting effector T cells. This therapeutic pathway provides a safe treatment to preserve beta cell function in new-onset diabetic individuals with the GAD-Alum vaccine being the most extensively studied therapy. Insulin is being used in many forms to prevent diabetes and stop the underlying autoimmune process. For the future, combination immune therapies targeting different pathways in the immune system will be needed to effectively induce sustained tolerance in type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.